daratumumab + lenalidomide + ixazomib + dexamethasone

**Daratumumab + lenalidomide + ixazomib + dexamethasone** is an investigational quadruplet regimen for multiple myeloma, primarily evaluated in newly diagnosed or relapsed/refractory settings. It combines **daratumumab**, a CD38-targeting monoclonal antibody that induces tumor cell death via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and direct apoptosis; **lenalidomide**, an immunomodulatory agent that enhances immune response and inhibits myeloma cell proliferation; **ixazomib**, an oral proteasome inhibitor that disrupts protein degradation leading to myeloma cell apoptosis; and **dexamethasone**, a corticosteroid that reduces inflammation and myeloma cell survival. Developed through clinical trials like NCT04009109, it aims to deepen responses and improve progression-free survival, particularly in transplant-ineligible patients, with fixed-duration induction followed by maintenance in some protocols.[6][8][11][13]

Other names

Dara-Ixa-RdD-IxaRd